Revolution MD is a biotech innovator focused on controlling how opioids are safely dispensed. Flagship Capital Legacy Fund is a social impact/ESG fund.
KNOXVILLE, TN, April 13, 2022 /24-7PressRelease/ — Revolution MD Inc. (“Revolution MD), a biotech innovator focused on controlling how opioids are safely dispensed, today announced the execution of a non-binding Letter of Intent with Flagship Capital Legacy Fund (“Flagship Capital”). Flagship Capital Legacy Fund is a social impact/ESG fund focused on 4 key areas. Waste to Energy, Ocean Cleanup, Opioid Crisis and Alternative solutions to helping small businesses recover from the Covid19 pandemic.
Under terms of the above-mentioned Letter of Intent, dated April 7, 2022, Flagship Capital Legacy Fund intends to make an investment of $2M ($2,000,000) – $5M ($5,000,000.00) in exchange for an equity stake in Revolution.
Revolution MD President Mr. Josh Kimmel stated “This is a significant and timely investment that will allow us to add substantial value to the Company and its shareholders by achieving important milestones in our effort to address a critical component of the Opioid Crisis.
Casey Pond Principal of Flagship Capital stated, “We have been thoroughly impressed with the unique and innovative approach to address a root cause of the Opioid Epidemic, in addition to the world class talent the Company has assembled. Revolution MD is a valuable addition to our portfolio.”
About Revolution MD Inc.
Revolution MD is based Knoxville, TN and was incorporated in 2018. Revolution MD has developed a solution to address the root cause of the opioid epidemic, by controlling how opioids are dispensed. The Company is developing a patented Smart Inhaler controlled by a proprietary blockchain network that utilizes biometric authentication and physical abuse deterrents. The network provides real time connectivity and control of the device allowing interfaces with health care providers, enables remote activation and deactivation and the ability to taper patients off the medication. The data captured by the network is invaluable for various stakeholders including pharmaceutical companies, health care professionals, prescribing physicians, law enforcement and regulatory agencies.
About Flagship Capital Legacy Fund
Flagship Capital Legacy Fund is a social impact/ESG fund, with 4 key areas of focus: Waste to Energy, Ocean Cleanup, Opioid Crisis and Alternative solutions to helping small businesses recover from the Covid19 pandemic.
Mr. Joshua Kimmel
Tel: +1(865) 329-6792
SOURCE Revolution MD Inc.
For more information go to Rev-MD.com https://www.startengine.com/revolution-md
For the original version of this press release, please visit 24-7PressRelease.com here